Olodaterol

證據等級: L5

預測適應症: 4 個

Olodaterol: From COPD to Bronchitis

One-Sentence Summary

Olodaterol is a long-acting β2-adrenergic agonist (LABA) already established, per the supporting literature in this evidence pack, as a once-daily maintenance bronchodilator for Chronic Obstructive Pulmonary Disease (COPD). The TxGNN model additionally predicts efficacy for Bronchitis, currently supported by 3 clinical trials and 2 publications — with a closely related “Obstructive Lung Disease” prediction (same drug, overlapping mechanism) backed by substantially stronger evidence (50+ trials, including multiple completed Phase 3 RCTs).

Quick Overview

Item	Content
Original Indication	Chronic Obstructive Pulmonary Disease (COPD) — established via literature evidence in this pack; no Danish label data available
Predicted New Indication	Bronchitis
TxGNN Prediction Score	99.84%
Evidence Level	L3
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for olodaterol is not available in this evidence pack (a High-severity data gap). Based on the supporting literature retrieved, olodaterol is a once-daily inhaled long-acting β2-adrenoceptor agonist (LABA) that relaxes bronchial smooth muscle via β2-receptor stimulation, and its efficacy as a maintenance bronchodilator in COPD has been established (e.g., PMID 25773742, 31119643, 27354040).

Bronchitis — particularly chronic bronchitis — is clinically a component phenotype of COPD rather than a distinct disease category, so the mechanistic rationale for extending olodaterol’s use is strong: the same airway smooth-muscle relaxation and bronchodilation that benefits COPD patients directly addresses the airflow obstruction and bronchial inflammation seen in bronchitis. This is corroborated by the supporting trials themselves, several of which explicitly enrolled patients with “COPD (Chronic Bronchitis, Emphysema)” (e.g., NCT02850978).

Notably, the evidence pack also contains a second, closely related predicted indication — “Obstructive Lung Disease” — for the same drug, supported by over 50 clinical trials including multiple completed Phase 3 RCTs (e.g., TONADO 1/2, DYNAGITO). This much larger evidence base reinforces the mechanistic plausibility of the bronchitis prediction, though the bronchitis-specific evidence itself remains limited to observational/post-marketing studies.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT05127304	N/A (observational)	Completed	11,316	Compared healthcare resource utilization and clinical outcomes of Tiotropium/Olodaterol vs. Fluticasone Furoate/Umeclidinium/Vilanterol in COPD patients
NCT03333018	N/A (observational)	Completed	22,155	Post-authorisation drug utilisation study describing patterns of use of aclidinium (mono/combination) vs. other COPD medications, including off-label use assessment
NCT02850978	N/A (observational)	Completed	1,335	Long-term post-marketing surveillance of Tiotropium+Olodaterol FDC (Spiolto) in Japanese patients with COPD, including chronic bronchitis and emphysema

Literature Evidence

PMID	Year	Type	Journal	Key Findings
27354040	2016	Review	American Journal of Health-System Pharmacy	Reviews pharmacology, pharmacokinetics, efficacy, and safety of once-daily LABA olodaterol
25515181	2015	Guideline/Review	Basic & Clinical Pharmacology & Toxicology	Finnish national COPD guideline covering diagnosis, assessment, and pharmacotherapy of stable COPD

Denmark Market Information

Olodaterol is currently not marketed in Denmark, and no marketing authorisations (national Laegemiddelstyrelsen or centralised EMA) are on record in this evidence pack.

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. (Note: this evidence pack flags TFDA label warnings/contraindications as a Blocking data gap, meaning safety data is currently insufficient for an S1 safety pre-assessment.)

Conclusion and Next Steps

Decision: Hold

Rationale:

The bronchitis-specific evidence (predicted_indications[0]) is limited to 3 observational/post-marketing studies and 2 non-RCT publications (Evidence Level L3), and olodaterol is not currently marketed in Denmark.
A Blocking data gap exists for TFDA/SmPC warnings and contraindications, which prevents any safety pre-assessment (S1) from proceeding.

To proceed, the following is needed:

Approved SmPC / product label with warnings, contraindications, and drug interaction data
Confirmed mechanism of action documentation (currently a data gap)
Consideration of whether “Obstructive Lung Disease” (the closely related prediction with 50+ trials and multiple completed Phase 3 RCTs) should be evaluated as the primary repurposing target instead of bronchitis specifically
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.